Wire · opportunities
FDA Approves Lirafugratinib Capsules for FGFR2+ Cholangiocarcinoma Care
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
The FDA has approved lirafugratinib (Lyrfigtu) for adults with previously treated, unresectable or metastatic FGFR2-rearranged cholangiocarcinoma, based on a 46% overall response rate in the REFOCUS trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
FDA approval of lirafugratinib opens a new rare cancer treatment pathway you can now build on for FGFR2-positive cholangiocarcinoma. This signals rising demand for targeted therapies in this oncology niche.
◆ Coverage
10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026
◆ Related on Wire
◆ Topics